Modality
Cell Therapy
MOA
TROP-2 ADC
Target
GIP-R
Pathway
Sphingolipid
CFCML
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
~Feb 2023
→ ~May 2024
Phase 2
Aug 2024
→ Dec 2028
Phase 2Current
NCT06555344
2,425 pts·CF
2024-08→2028-12·Terminated
2,425 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-092.7y awayPh2 Data· CF
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2028-12-09 · 2.7y away
CF
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06555344 | Phase 2 | CF | Terminated | 2425 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |